Product image of Inlyta (Axitinib) supplied by GNH India

Inlyta

Active Ingredient:
Axitinib
Origin:
EU

Inlyta (Axitinib)

Axitinib, the active ingredient in Inlyta, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats metastatic renal cell carcinoma in adult patients.\n\nGNH India supplies Inlyta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pfizer Europe Ma Eeig

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Inlyta is a targeted anti‑angiogenic agent used in the management of renal cell carcinoma.\n\nMetastatic renal cell carcinoma: improves progression‑free survival and delays disease progression.

How It Works

  • Axitinib selectively inhibits the intracellular tyrosine kinase activity of vascular endothelial growth factor receptors VEGFR‑1, VEGFR‑2 and VEGFR‑3. By blocking these receptors, the drug reduces VEGF‑driven signaling pathways that promote tumor angiogenesis, leading to decreased blood vessel formation and tumor growth inhibition.

Side Effects

  • Common Side Effects:\n- Hypertension\n- Diarrhea\n- Fatigue\n- Nausea\n- Decreased appetite\n- Hand‑foot syndrome\n\nSerious or Rare Side Effects:\n- Arterial thromboembolic events\n- Gastrointestinal perforation or fistula\n- Hepatic failure\n- Severe hemorrhage\n- Wound healing complications\n- Life‑threatening hypertension

Precautions & Warnings

  • Patients should be monitored regularly for cardiovascular and hepatic safety.\n\nMonitor blood pressure: check regularly and manage hypertension promptly\nAssess liver function: perform baseline and periodic hepatic enzyme tests\nEvaluate bleeding risk: avoid concomitant anticoagulants unless necessary\nReview cardiovascular history: caution in patients with prior arterial events\nAdjust dose in hepatic impairment: follow prescribing guidance for liver dysfunction\nStore at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

  • Axitinib may interact with several drug classes, requiring careful management.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase axitinib exposure\n- Strong CYP3A4 inducers (e.g., rifampin): may reduce axitinib efficacy\n- Anticoagulants (e.g., warfarin): increased risk of bleeding\n\nModerate Interactions (Monitor Closely):\n- NSAIDs: may exacerbate hypertension and bleeding risk\n- Diuretics: may affect blood pressure control\n- CYP2C19 inhibitors (e.g., fluoxetine): modest increase in axitinib levels\n- CYP2C9 inhibitors (e.g., amiodarone): potential elevation of plasma concentrations\n- St. John’s wort: may lower axitinib concentrations

Frequently Asked Questions

Inlyta (axitinib) is indicated for the treatment of metastatic renal cell carcinoma in adult patients. It works as an anti‑angiogenic therapy to slow tumor growth by inhibiting blood vessel formation.

Axitinib selectively blocks the tyrosine kinase activity of VEGFR‑1, VEGFR‑2 and VEGFR‑3. This inhibition disrupts VEGF‑mediated signaling, reducing tumor angiogenesis and limiting the supply of nutrients needed for cancer cell proliferation.

The prescribed dose of Inlyta is determined by the treating physician based on individual patient factors, disease status, and tolerance. Patients should follow the dosing instructions provided by their healthcare professional.

Inlyta is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy unless clearly needed. Breastfeeding is not recommended while on treatment because the drug may be excreted in milk.

To order Inlyta, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Inlyta (axitinib) is a selective VEGFR inhibitor with a relatively short half‑life, allowing rapid dose adjustments. Compared with broader‑spectrum agents like sunitinib, axitinib offers more specific VEGFR targeting, which may result in a different side‑effect profile and dosing flexibility.

Inlyta tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged.

Inlyta is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew it.

Serious risks include severe hypertension, arterial thromboembolic events, gastrointestinal perforation, hepatic failure, and significant bleeding. Patients should be monitored closely for these events and report any concerning symptoms immediately.

Inlyta should not be used in patients with uncontrolled hypertension, recent arterial thrombotic events, active gastrointestinal perforation, severe hepatic impairment, or in pregnant women unless the benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Axitinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT